MedTrace Logo

Artemisinin Resistance In Malaria Treated With IV Artesunate

NCT02640495 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-08-22

No results posted yet for this study

Summary

The spread of artemisinin resistant falciparum malaria presents new challenges to both the control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might jeopardize the use of parenteral artesunate as the first line drug for the treatment of severe falciparum malaria.

The purpose of this study is to assess the effect of artemisinin resistance (defined by a Kelch13 mutation with known functional significance) in P. falciparum malaria requiring parenteral artesunate treatment on lactate clearance parameters.

Conditions

Interventions

DRUG

Intravenous Artesunate as part of standard medical practice

Intravenous Artesunate 2.4 mg/kg

Sponsors & Collaborators

  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER

  • Oxford University Clinical Research Unit, Vietnam

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Prof. Arjen M Dondorp, MD · Mahidol Oxford Research Unit (MORU)

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640495 on ClinicalTrials.gov